Clinical Trial Update: Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy [Phase 2]

View source ↗

Summary

Phase II multicenter study of IMC-A12 (cixutumumab) in thymoma and thymic carcinoma patients who had prior chemotherapy; results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thymic Carcinoid
• Thymic Carcinoma
• Thymic Neuroendocrine Tumor
• Thymoma

Drugs mentioned

• IMC-A12 (cixutumumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Thymoma, Thymic Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2012-11-14